The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

被引：0
|
作者：
Gordon, Max J.
Kaempf, Andy
Sitlinger, Andrea
Salous, Tareq
Alqahtani, Hamood
Churnetski, Michael C.
Wisniewski, Paul
Rivera, Xavier Issac
Patel, Krish
Persky, Daniel O.
Cohen, Jonathon B.
Choi, Michael Y.
Hill, Brian T.
Shadman, Mazyar
Stephens, Deborah M.
Brander, Danielle M.
Park, Byung
Danilov, Alexey
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136808
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study
    Thompson, Philip A.
    Levy, Vincent
    Tam, Constantine S.
    Al Nawakil, Chadi
    Goudot, Francois Xavier
    Quinquenel, Anne
    Ysebaert, Loic
    Michallet, Anne-Sophie
    Dilhuydy, Marie Sarah
    Van den Neste, Eric W.
    Dupuis, Jehan
    Keating, Michael
    Meune, Christophe
    Cymbalista, Florence
    BLOOD, 2016, 128 (22)
  • [22] Hodgkin lymphoma transformation of chronic lymphocytic leukemia (CLL) in a patient under ibrutinib therapy
    Kalpadakis, Christina
    Pangalis, Gerassimos
    Sachanas, Sotirios
    Zaroulis, Chrysothea
    Moschogiannis, Maria
    Yiakoumis, Xanthi
    Koulieris, Efstathios
    Tsirkinidis, Pantelis
    Rontogiannis, Dimitra
    LEUKEMIA & LYMPHOMA, 2017, 58 : 194 - 194
  • [23] A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study
    Gordon, Max J.
    Sitlinger, Andrea
    Salous, Tareq
    Alqahtani, Hamood
    Churnetski, Michael
    Rivera, Xavier
    Wisniewski, Paul
    Cohen, Jonathon
    Patel, Krish
    Shadman, Mayzar
    Choi, Michael
    Hill, Brian
    Stephens, Deborah
    Persky, Daniel
    Brander, Danielle
    Danilov, Alexey V.
    LEUKEMIA RESEARCH, 2020, 89
  • [24] USEFULNESS OF THE PROGNOSTIC ESTIMATION OF THE CLL-IPI INDEX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDER TREATMENT WITH IBRUTINIB
    Perez, Lamas Lucia
    Marquet, Palomanes Juan
    Nunez-Torron, Claudia
    Jimenez, Chillon Carlos
    Astibia, Mahillo Beatriz
    Piris, Villaespesa Miguel
    Martin, Moro Fernando
    Lario, Arribas Ana
    Herrera, Puente Pilar
    Lopez, Jimenez Javier
    HAEMATOLOGICA, 2020, 105 : 64 - 65
  • [25] Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL)
    Molica, Stefano
    Lentini, Mirella
    Zappala, Daniela
    Levato, Luciano
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2778 - 2780
  • [26] Dynamic prognostication in an unselected cohort of patients with chronic lymphocytic leukemia (CLL)
    Klaus, J.
    Schlosser, P.
    Hieke, S.
    Szic, Szarc Vel K.
    Hild, S.
    Gumpp, V
    Mertelsmann, R.
    Duyster, J.
    Zirlik, K.
    Schumacher, M.
    Claus, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 171 - 171
  • [27] High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy
    Fleury, Carole
    Quinquenel, Anne
    Fornecker, Luc-Matthieu
    Ysebaert, Loic
    Thieblemont, Catherine
    Zini, Jean-Marc
    Feugier, Pierre
    Willems, Lise
    Collon, Jean-Francois
    Eclache, Virginie
    Lazarian, Gregory
    Letestu, Remi
    Cymbalista, Florence
    Baran-Marszak, Fanny
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S217 - S218
  • [28] CHROMOSOMAL STUDY OF PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
    FORT, S
    KANTER, RJ
    PHILLIPS, EA
    RAI, KR
    SAWITSKY, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 429 - 429
  • [29] The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice
    Finnes, Heidi D.
    Chaffee, Kari G.
    Call, Timothy G.
    Ding, Wei
    Bowen, Deborah A.
    Conte, Michael
    McCullough, Kristen B.
    Merten, Julianna A.
    Bartoo, Gabriel T.
    Smith, Matthew D.
    Schwager, Susan M.
    Slager, Susan L.
    Kay, Neil E.
    Shanafelt, Tait D.
    Parikh, Sameer A.
    BLOOD, 2015, 126 (23)
  • [30] Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Kipps, Thomas J.
    Fraser, Graeme
    Coutre, Steven
    Brown, Jennifer R.
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Byrd, John C.
    O'Brien, Susan M.
    Dilhuydy, Marie-Sarah
    Devereux, Stephen
    Jaeger, Ulrich
    Moreno, Carol
    Cramer, Paula
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    Mahler, Michelle
    Salman, Mariya
    Cheng, Mei
    Londhe, Anil
    Ninomoto, Joi
    Howes, Angela
    James, Danelle
    Hallek, Michael
    CANCER RESEARCH, 2017, 77
12345